[The first vaccine for prevention of cervix cancer and other human papillomavirus related diseases gets a positive evaluation by the European Drug Authority].
D000293:Adolescent; D000328:Adult; D052685:Alphapapillomavirus / Q000276:immunology*; D002648:Child; D003218:Condylomata Acuminata / Q000276:immunology / Q000451:nursing* / Q000473:pathology / Q000517:prevention & control*; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D005260:Female; D005858:Germany; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D009367:Neoplasm Staging; D030361:Papillomavirus Infections / Q000276:immunology / Q000451:nursing* / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000276:immunology / Q000627:therapeutic use*; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000451:nursing* / Q000473:pathology / Q000517:prevention & control*; D002578:Uterine Cervical Dysplasia / Q000276:immunology / Q000451:nursing* / Q000473:pathology / Q000517:prevention & control*
D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines